KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBITDA (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EBITDA for 15 consecutive years, with $113.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 221.15% year-over-year to $113.2 million, compared with a TTM value of $334.1 million through Dec 2025, up 215.49%, and an annual FY2025 reading of $328.2 million, up 213.44% over the prior year.
  • EBITDA was $113.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $300.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $300.9 million in Q3 2025 and bottomed at -$407.5 million in Q3 2022.
  • Average EBITDA over 5 years is -$118.0 million, with a median of -$148.7 million recorded in 2023.
  • The sharpest move saw EBITDA plummeted 166.73% in 2024, then skyrocketed 395.66% in 2025.
  • Year by year, EBITDA stood at -$257.5 million in 2021, then increased by 19.08% to -$208.4 million in 2022, then soared by 38.13% to -$128.9 million in 2023, then increased by 27.5% to -$93.5 million in 2024, then surged by 221.15% to $113.2 million in 2025.
  • Business Quant data shows EBITDA for ALNY at $113.2 million in Q4 2025, $300.9 million in Q3 2025, and -$58.7 million in Q2 2025.